MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/pbc.31767

Медицинская библиотека · Pediatric blood & cancer · 2025

Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001.

Ramjan Sameera, Blair Thies Melanie, Li Yuelin, Thrope Alexandra, Silverman Lewis, Welch Jennifer J G, Kahn Justine, Kelly Kara M, Tran Thai-Hoa, Michon Bruno, Gennarini Lisa, Bona Kira, Park Yongkyu, Cole Peter D, Sands Stephen A

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

This study describes neurocognitive functioning during the first month of induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) and associations with age, sex, risk of relapse, maternal education, household material hardship (HMH), and oxidative stress.

METHODS

Patients treated on protocol 16-001 (NCT03020030) across eight North American sites (2017-2022) consented for optional testing using Cogstate at six timepoints throughout treatment. The baseline data presented were collected within the first month after diagnosis.

RESULTS

Among 406 eligible patients, 330 (81%) consented (53% males, mean age = 8.8 years, SD = 4.7). Over 63% of participants performed within normal limits for their age range. Additionally, no relationship was observed at baseline between neurocognition and maternal education, HMH, or oxidative stress. In contrast, a linear relationship was observed between older age and weaker psychomotor speed (p < 0.0001), attention (p < 0.0001), and working memory (p = 0.019). Males also demonstrated faster psychomotor speed (p = 0.0027), while females demonstrated stronger visual learning (p = 0.011). Furthermore, having a higher risk of relapse was associated with slower psychomotor speed (p = 0.006) and weaker attention (p = 0.033).

CONCLUSIONS

Our findings indicate that most ALL patients in this study who were assessed at baseline did not display cognitive impairments, except for a small subset of participants who were below age expectations across domains. These baseline findings also identify subgroups based upon age, sex, and ALL risk classification that begin medical treatment with neurocognitive delays, warranting monitoring to elucidate whether exposure to therapy further impacts these domains. Additionally, the lack of impact on neurocognitive functioning at baseline of maternal education, HMH, and/or oxidative stress enables subsequent assessments to effectively identify the potential emergence of deficits as a result of exposure to medical treatment.

Для цитирования: Ramjan Sameera, Blair Thies Melanie, Li Yuelin, Thrope Alexandra, Silverman Lewis, Welch Jennifer J G, Kahn Justine, Kelly Kara M, Tran Thai-Hoa, Michon Bruno, Gennarini Lisa, Bona Kira, Park Yongkyu, Cole Peter D, Sands Stephen A. Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001.. Pediatric blood & cancer. 2025. DOI: 10.1002/pbc.31767.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.